From: Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients
Total cohort of patients (n = 44) | RA patients evaluated for TCRBV a repertoire and TERT b (n = 17) | p | |
---|---|---|---|
Sex (male/female) | 6/38 | 4/13 | 0.300 |
Age, years (range) | 54 (47-60) | 57 (48-60) | 0.412 |
Rheumatoid factor positivity | 33 (75%) | 12 (70%) | 0.979 |
AntiCCPc positivity | 36 (82%) | 15 (88%) | 0.825 |
Disease duration, years (range) | 8 (4-13) | 4 (2-7) | 0.001 |
Smokers | 14 (32%) | 7 (41%) | 0.697 |
Comorbidities: | |||
Arterial hypertension | 17 | 4 | 0.416 |
Diabetes mellitus | 4 | 1 | 0.223 |
Cardio-vascular events | 4 | 0 | 0.478 |
Number of previous DMARDsd | 3 (2-5) | 2 (2-3) | 0.001 |
Previous biological agents: | |||
Infliximab | 21 | 5 | 0.313 |
Etanercept | 27 | 8 | 0.256 |
Adalimumab | 28 | 9 | 0.635 |
Rituximab | 9 | 1 | 0.321 |
Tocilizumab | 4 | 3 | 0.623 |
Anakinra | 6 | 2 | 0.999 |
DAS28-CRP at baseline (range) | 5.10 (4.40-5.97) | 5.06 (4.41-5.46) | 0.185 |
Median dosage of methotrexate at baseline (range) | 12.5 (6.25-15) | 15 (10-15) | 0.042 |
Median number of DMARDs at baseline (range) | 1 (1-1) | 1 (1-1) | 0.022 |